New Market Report Now Available: Generex Biotechnology Corporation - Product Pipeline Review - 2014

Fast Market Research recommends "Generex Biotechnology Corporation - Product Pipeline Review - 2014" from Global Markets Direct, now available

Logo

Boston, MA -- (SBWire) -- 03/04/2014 --Global Market Direct's pharmaceuticals report, "Generex Biotechnology Corporation - Product Pipeline Review - 2014" provides data on the Generex Biotechnology Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Generex Biotechnology Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Generex Biotechnology Corporation and industry-specific third party sources, put together by Global Markets Direct's team.

Report Scope

- Generex Biotechnology Corporation - Brief Generex Biotechnology Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Generex Biotechnology Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Generex Biotechnology Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Generex Biotechnology Corporation's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Generex Biotechnology Corporation's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Generex Biotechnology Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Generex Biotechnology Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Generex Biotechnology Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Generex Biotechnology Corporation and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Generex Biotechnology Corporation - Product Pipeline Review - 2013
- Genzyme Corporation - Product Pipeline Review - 2014
- AmpliPhi Biosciences Corporation - Product Pipeline Review - 2014
- Melanoma - Pipeline Review, H2 2013
- Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014
- Influenza - Pipeline Review, H2 2013
- Genzyme Corporation - Product Pipeline Review - 2013
- Melanoma - Pipeline Review, H1 2013
- Mitsubishi Tanabe Pharma Corporation - Product Pipeline Review - 2013
- Aphios Corporation - Product Pipeline Review - 2013

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/468066